美国安进地舒单抗注射液哪里能买到

It is the first approved monoclonal antibody specifically targeting RANK ligand. RANK ligand is a transmembrane or soluble protein that is necessary for osteoclasts to maintain their structure, function, and survival. On May 28, 2010, the European Commission approved denosumab for the treatment of bone loss associated with hormone suppression in postmenopausal women with osteoporosis and prostate cancer. It can also be used in patients who are currently ineffective or intolerant to other treatments to reduce the risk of fractures.

Desosumab is produced by Amgen of the United States and was approved for marketing by the FDA in 2010. In terms of therapeutic effects, denosumab has a high affinity for RANKL. By preventing RANK ligands from activating RANK on the surface of osteoclasts, it inhibits osteoclast activation and development, reduces bone absorption, increases bone density and bone strength of both cortical bone and trabecular bone, promotes bone reconstruction, and reduces vertebrae and bone loss in postmenopausal women with osteoporosis. Incidence of nonvertebral and hip fractures.

Where can I buy Amgen denosumab injection in the United States?

Founded in 1980, Amgen has become one of the world's leading independent biotechnology companies, providing innovative drugs to millions of patients in more than 100 countries and regions around the world, and also has a number of promising drugs under development. At present, the denosumab injection produced by Amgen has been launched in my country, which means that patients can buy it in some domestic pharmacies with a prescription issued by a doctor, but the price of the original drug is usually relatively high.

In addition to domestic original drugs, Amgen of the United States has a relatively low price on the market in Turkey. The specification is 120 mg and the price is around $1,500. If it is inconvenient for patients to go to Turkey to buy it, please consult the medical companion and travel service to learn about the formal purchase method of denosumab.

Recommended related hot articles: /newsDetail/91055.html